Aggressive B-cell lymphomas: female BMI tied to R-CHOP-14 outcomes

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In women aged >60 years with aggressive B-cell lymphomas treated with R-CHOP-14 (rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisolone at 14-day intervals), obesity was a risk factor for inferior event-free survival (EFS), PFS, and OS.

Why this matters

  • Data regarding outcomes in obese patients with lymphoma are inconsistent.

Study design

  • RICOVER-60 data for 576 patients with aggressive B-cell lymphomas who received R-CHOP-14.
  • Results were analyzed according to BMI (≥30 kg/mvs 2) and sex.
  • All patients were aged >60 years.
  • Funding: Deutsche Krebshilfe.

Key results

  • 42% of patients were overweight (BMI: ≤25 to 2), 19% of patients were obese (BMI: ≥30 kg/m2) at treatment initiation.
  • No significant difference in all patients vs male patients for EFS, PFS, and OS.
  • Superior outcomes in nonobese females vs obese females for EFS (P=.041), PFS (P=.038), and OS (P=.031); results were confirmed in multivariate analyses adjusted for International Prognostic Index risk factors.
  • Some centers capped chemoimmunotherapy dose in patients with body surface area (BSA) >2 m2; no significant difference in EFS, PFS, or OS, regardless of sex or cyclophosphamide reduction due to high BSA.

Limitations

  • Retrospective data.